Thrombotic Complications after Hematopoietic Stem Cell Transplantation and other Cellular Therapies DOI Creative Commons
Paschalis Evangelidis, Eleni Gavriilaki, Dimitrios Α. Tsakiris

et al.

Thrombosis Update, Journal Year: 2024, Volume and Issue: 16, P. 100186 - 100186

Published: Aug. 7, 2024

Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) immunotherapy are widely used for the management of hematological malignancies. HSCT can be complicated by endothelial injury syndromes, such as HSCT-thrombotic microangiopathy (HSCT-TMA) sinusoidal obstructive syndrome/ veno-occlusive disease (SOS/VOD), which life-threatening. Moreover, venous thromboembolic events (VTEs) common in recipients due to injury, use central catheters, prolonged hospitalization, development a procoagulant state. VTEs have also been reported post-CAR-T infusion. The thrombotic these patients is challenging, high risk bleeding that present. CAR-T might followed toxicities, cytokine release syndrome (CRS) immune effector cell-associated neuro-toxicity (ICANS). Endothelial dysfunction implicated pathogenesis syndromes. Early recognition above complications crucial better outcomes our patients.

Language: Английский

Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb DOI Creative Commons

Evlampia Strongyli,

Paschalis Evangelidis, Ioanna Sakellari

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(5), P. 591 - 591

Published: May 6, 2024

Immunotherapy with chimeric antigen receptor T (CAR-T) cell therapies has brought substantial improvement in clinical outcomes patients relapsed/refractory B neoplasms. However, complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS) limit the therapeutic efficacy of this treatment approach. ICANS can have a broad range manifestations, while various scoring systems been developed for its grading. Cognitive decline is prevalent CAR-T therapy recipients including impaired attention, difficulty item naming, writing, agraphia, executive dysfunction. In review, we aim to present diagnostic methods tests that used recognition cognitive impairment these patients. Moreover, up-to-date data about duration symptoms after infusion are presented. More research on risk factors, pathogenesis, preventive measures, neurocognitive crucial better our

Language: Английский

Citations

3
Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside DOI Creative Commons
Nikolaos Evangelidis, Nikolaos Kotsiou, Paschalis Evangelidis

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(6), P. 5147 - 5160

Published: May 23, 2024

Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological inhibition of factor VIII (FVIII) hemostatic pathway leading to hemorrhagic events. Different domains FVIII are target autoantibodies (mainly immunoglobulin (Ig) G) deficiency FVIII. Several factors have been associated with activation auto-immunity towards Emerging evidence implicates CD4+ T cell in mediating this autoimmune response, their involvement like that observed congenital A. genes such as HLA II DRB*16, DQB1*0502, and CTLA-4 + 49 responsible for pathogenesis AHA. Epigenetic modifications mainly long-coding RNAS (lncRNAs) potentially contributing The treatment approach AHA includes management acute events administration immunosuppressive medications. This review aimed summarize published data on genetics epigenetics severity mortality disease creating an emerging need further research field acquired disorder.

Language: Английский

Citations

3
ADAMTS13 in the New Era of TTP DOI Open Access
Anna Papakonstantinou, Panagiotis Kalmoukos,

Aikaterini Mpalaska

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(15), P. 8137 - 8137

Published: July 26, 2024

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening, often immune-mediated disease that affects 2–13 persons per million year. Hemolytic anemia, thrombocytopenia, and end-organ damage due to the formation of microthrombi are characteristic TTP. ADAMTS13 disintegrin, metalloproteinase, cleaving protein von Willebrand factor (VWF) processes VWF multimers prevent them from interacting with platelets and, in turn, microvascular thrombosis. Prompt diagnosis TTP critical yet challenging. microangiopathies have similar clinical presentation. Measurement activity helps differential diagnosis. Less than 10% indicative Laboratory assays include incubating test plasma substrate (full-length VWM multimers) detection direct or indirect measurement cleavage product. The purpose this study examine diagnostic potential, advantages, weaknesses potency

Language: Английский

Citations

3
Thrombotic Complications after Hematopoietic Stem Cell Transplantation and other Cellular Therapies DOI Creative Commons
Paschalis Evangelidis, Eleni Gavriilaki, Dimitrios Α. Tsakiris

et al.

Thrombosis Update, Journal Year: 2024, Volume and Issue: 16, P. 100186 - 100186

Published: Aug. 7, 2024

Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) immunotherapy are widely used for the management of hematological malignancies. HSCT can be complicated by endothelial injury syndromes, such as HSCT-thrombotic microangiopathy (HSCT-TMA) sinusoidal obstructive syndrome/ veno-occlusive disease (SOS/VOD), which life-threatening. Moreover, venous thromboembolic events (VTEs) common in recipients due to injury, use central catheters, prolonged hospitalization, development a procoagulant state. VTEs have also been reported post-CAR-T infusion. The thrombotic these patients is challenging, high risk bleeding that present. CAR-T might followed toxicities, cytokine release syndrome (CRS) immune effector cell-associated neuro-toxicity (ICANS). Endothelial dysfunction implicated pathogenesis syndromes. Early recognition above complications crucial better outcomes our patients.

Language: Английский

Citations

1